Sensei Biotherapeutics has ended development of its lead candidate solnerstotug, a VISTA‑targeting monoclonal antibody that had shown a 14% overall response rate in patients with “hot” tumors during the dose‑expansion phase of its Phase 1/2 trial.
The company will conduct a comprehensive strategic review of alternatives, including asset sales, licensing, collaborations, a potential sale of the company, a business combination, or an orderly wind‑down of operations.
To preserve cash, Sensei will reduce its workforce, retaining a small core team to manage regulatory compliance and oversee the orderly cessation of development activities.
Cash on hand was $28.60 million as of June 30 2025, which the company estimates will fund operations into the second quarter of 2026. The decision to discontinue solnerstotug reflects the company’s assessment that continued investment in the program is unsustainable given the limited runway and the need to secure additional capital.
In prior periods, Sensei reported a net loss of $4.9 million for the quarter ended June 30 2025, compared with a $7.1 million loss for the same quarter in 2024. Research and development expenses were $2.5 million in Q2 2025, down from $4.6 million in Q2 2024.
The company’s previous restructuring in late 2024 included a 46% workforce reduction and the closure of its Rockville research site to focus resources on solnerstotug clinical development.
Sensei recently regained Nasdaq compliance following a 1‑for‑20 reverse stock split effective in June 2025.
The VISTA pathway remains an area of active research, but competition for PD‑(L)1 resistant tumors is intense, and treatment options are limited.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.